Trials / Completed
CompletedNCT02810964
Sulforaphane to Reduce Symptoms of Schizophrenia
A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Sheppard Pratt Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sulforaphane Nutraceutical | Sulforaphane Nutraceutical 6 tablets by mouth daily |
| DRUG | Identical-appearing Placebo | Identical-appearing Placebo 6 tablets by mouth daily |
Timeline
- Start date
- 2017-02-22
- Primary completion
- 2019-11-11
- Completion
- 2019-11-11
- First posted
- 2016-06-23
- Last updated
- 2021-07-27
- Results posted
- 2021-07-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02810964. Inclusion in this directory is not an endorsement.